Ronald Krauss, MD
Basic profileEndocrinology, Diabetes & Metabolism
Ronald Krauss is an Endocrinology/Metabolic physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- The Mediterranean Full-Fat Dairy Study
Sponsor: UCSF Benioff Children's Hospital Oakland
- Soda and Milk Study
Sponsor: UCSF Benioff Children's Hospital Oakland
- Effects of Almond Intake on Atherogenic Lipoprotein Particles
Sponsor: UCSF Benioff Children's Hospital Oakland
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Corcept TherapeuticsProgram year20251 payment$77
- Esperion Therapeutics, Inc.Program year20252 payments$42
- Abbott LaboratoriesProgram year20241 payment$124
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
92.5%Statin53.4%Rosuvastatin Calcium66%Atorvastatin Calcium19%Pravastatin Sodium15%Part D<11 patientsCholesterol absorption inhibitor29.2%Ezetimibe100%Part D≥19 patients+ 1 more class in this area
Hormonal (systemic)
7.5%l-Thyroxine7.5%Synthroid100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
13 NIH research awards on record, funded 1985–2020 per NIH RePORTER. The latest:
- Statin Treatment and Incident Alzheimer's Disease and Related Dementias in a Large, Multi-ethnic Health Plan
Kaiser Foundation Research Institute
FY2020$2,999,547RF1AG069259 - Pharmacogenomics of Statin Therapy
Children'S Hospital & Res Ctr at Oakland
FY2019$1,524,688P50GM115318 - Pharmacogenomics of Statin Therapy
University of California, San Francisco
FY2019$1,173,979P50GM115318
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”